This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): RAV12
Description: RAV12 is a high affinity IgG1 chimeric monoclonal antibody that recognizes a primate restricted, N-linked carbohydrate epitope (glycotope RAAG12) expressed on a number of human carcinomas, including an especially high percentage (>90 percent) of adenocarcinomas of gastrointestinal origin.
Deal Structure: In November 2007, VaxGen and Raven biotechnologies announced that their respective boards of directors unanimously approved a definitive merger agreement.
In March 2008, Vaxgen and Raven terminated their merger agreement in light of stronger than anticipated opposition to the proposed merger by VaxGen stockholders.
In July 2008, MacroGenics announced the acquisition of Raven Biotechnologies.
Additional information available to subscribers only: